[go: up one dir, main page]

GB202012161D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB202012161D0
GB202012161D0 GBGB2012161.2A GB202012161A GB202012161D0 GB 202012161 D0 GB202012161 D0 GB 202012161D0 GB 202012161 A GB202012161 A GB 202012161A GB 202012161 D0 GB202012161 D0 GB 202012161D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2012161.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADC Therapeutics SA
Original Assignee
ADC Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA filed Critical ADC Therapeutics SA
Priority to GBGB2012161.2A priority Critical patent/GB202012161D0/en
Publication of GB202012161D0 publication Critical patent/GB202012161D0/en
Priority to PCT/EP2021/071861 priority patent/WO2022029223A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2012161.2A 2020-08-05 2020-08-05 Combination therapy Ceased GB202012161D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2012161.2A GB202012161D0 (en) 2020-08-05 2020-08-05 Combination therapy
PCT/EP2021/071861 WO2022029223A1 (en) 2020-08-05 2021-08-05 Combination therapy comprising anti-kaag1 antibody drug conjugate and parp inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2012161.2A GB202012161D0 (en) 2020-08-05 2020-08-05 Combination therapy

Publications (1)

Publication Number Publication Date
GB202012161D0 true GB202012161D0 (en) 2020-09-16

Family

ID=72425127

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2012161.2A Ceased GB202012161D0 (en) 2020-08-05 2020-08-05 Combination therapy

Country Status (2)

Country Link
GB (1) GB202012161D0 (en)
WO (1) WO2022029223A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SI1934174T1 (en) 2005-10-07 2011-08-31 Exelixis Inc Azetidines as mek inhibitors for the treatment of proliferative diseases
JP5503706B2 (en) 2012-08-14 2014-05-28 株式会社サンフロイント Poultice applicator
UA123889C2 (en) * 2017-02-08 2021-06-16 Ейдісі Терапьютікс Са PYROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

Also Published As

Publication number Publication date
WO2022029223A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
IL304223A (en) Combination therapy
IL319599A (en) Combination therapy
GB202103164D0 (en) Therapy
GB202004189D0 (en) Combination therapy
GB202002639D0 (en) Therapy
IL318268A (en) Combination therapy
GB202111288D0 (en) Combination therapy
GB202104037D0 (en) Combination therapy
GB202111035D0 (en) Therapy
GB202108303D0 (en) Therapy
GB202109375D0 (en) Combination therapy
GB202109377D0 (en) Combination therapy
GB202109373D0 (en) Combination therapy
GB202107824D0 (en) Combination therapy
GB202107713D0 (en) Combination therapy
GB202107706D0 (en) Combination therapy
GB202107709D0 (en) Combination therapy
GB202015916D0 (en) Combination therapy
GB202012161D0 (en) Combination therapy
GB202009178D0 (en) Combination therapy
GB202117706D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)